Modalis Therapeutics announces joint research agreement with JCR Pharmaceuticals
The collaboration is aimed at developing new gene therapies for undisclosed CNS diseases by leveraging JCR Pharmaceuticals' proprietary…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Dec 23
The collaboration is aimed at developing new gene therapies for undisclosed CNS diseases by leveraging JCR Pharmaceuticals' proprietary…
13 Dec 23
Funding comes on the heels of positive top-line clinical results and will advance clinical development of its lead…
12 Dec 23
BL-B01D1 is a bispecific topoisomerase inhibitor-based ADC, which is presently in a Phase 1 study in patients with…
12 Dec 23
The financing will be used to optimize breakthrough applications of the company’s Z-Screen platform and advance an internal…
11 Dec 23
The collaboration brings together professional advantages of Nona Biosciences and Evive Biotech, aiming to accelerate the process of…
08 Dec 23
The funding will be used to solidify the firm’s AlphaDirect technology, which is a Pb212 isolation method, and…
06 Dec 23
Under the terms of this arrangement, the French pharmatech firm will use its deep physics and generative AI…
06 Dec 23
Financing led by Ascenta Capital with participation from new and existing investors; Dr. Lorence Kim joins board of…
05 Dec 23
The partnership combines AstraZeneca's expertise in oncology R&D with Absci's Integrated Drug Creation platform to expedite the discovery…
05 Dec 23
The proceeds from the funding round will be used by the company to advance the Phase 1 proof-of-mechanism…